Fallopian tube cancer

27 trials 13 recruiting MedDRA PT
27 Registered trials
13 Recruiting
18 Unique sponsors
30 Unique IMPs
21 Commercial trials
Drug classes (ATC)
— ATC code not specified 11
L Oncology (ATC L) 14
S Ophthalmology/ENT (ATC S) 5
Mechanism of action (INN-stem analysis)
Unknown / small molecule 8 substances
PARP inhibitor 4 substances
Anthracycline 2 substances
Antimetabolite 2 substances
Taxane 2 substances
Checkpoint inhibitor (PD-1) 2 substances
Monoclonal antibody (angiogenesis) 1 substance
Platinum compound 1 substance
Antibody-drug conjugate (ADC) 1 substance
Corticosteroid 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
Monoclonal antibody (unknown source) 1 substance
Topoisomerase I inhibitor 1 substance
Monoclonal antibody 1 substance
Monoclonal antibody (rat) 1 substance
Monoclonal antibody (immune) 1 substance
Phase III: 8 Phase II/III: 1 Phase II: 10 Phase III/IV: 1 Phase IV: 1 Phase I: 1 Phase I (Other): 2 Phase I (First in Human): 3

Filter these 27 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 27 trials

Phase III

8 trials
  • AGO Research GmbH Commercial
    BEVACIZUMAB; CARBOPLATIN; NIRAPARIB; NIRAPARIB TOSILATE MONOHYDRATE; PACLITAXEL
    2024-516066-11-00 4 countries 2022 n=1,103
    Recruiting
  • AstraZeneca AB Commercial
    OLAPARIB
    2024-512982-15-00 12 countries 2021 n=94
    Recruiting
  • Canariabio Inc. Commercial
    OREGOVOMAB
    2024-519218-30-00 5 countries 2021 n=64 Orphan
    Ended
  • Corcept Therapeutics Inc. Commercial
    PACLITAXEL ALBUMIN-BOUND; RELACORILANT
    2024-514080-25-00 6 countries 2023 n=205 Orphan
    Ended
  • Immunogen Inc. Commercial
    DOXORUBICIN HYDROCHLORIDE; MIRVETUXIMAB SORAVTANSINE; PACLITAXEL; PREDNISOLONE ACETATE; TOPOTECAN
    2024-516111-25-00 1 country 2020 n=1 Orphan
    Ended
  • Mural Oncology Inc. Commercial
    NEMVALEUKIN ALFA; PEMBROLIZUMAB
    2024-513230-38-00 10 countries 2022 n=244
    Ended
  • pharmaand GmbH Commercial
    NIVOLUMAB; RUCAPARIB
    2024-516662-11-00 11 countries 2018 n=257
    Ended
  • Centre Oscar Lambret Academic
    IMP not specified
    2024-514706-31-01 2 countries 2019 n=352
    Ended

Phase II/III

1 trial
  • Daiichi Sankyo Inc. Commercial
    RALUDOTATUG DERUXTECAN
    2023-507914-28-00 9 countries 2024 n=344
    Recruiting

Phase II

10 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    CARBOPLATIN; MIRVETUXIMAB SORAVTANSINE; PREDNISOLONE ACETATE
    2022-501220-14-00 3 countries 2023 n=45 Orphan
    Recruiting
  • AbbVie Deutschland GmbH & Co. KG Commercial
    MIRVETUXIMAB SORAVTANSINE; PREDNISOLONE ACETATE
    2024-517184-23-00 4 countries 2025 n=37
    Recruiting
  • AGO Research GmbH Commercial
    CARBOPLATIN; DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL; GEMCITABINE HYDROCHLORIDE; NIRAPARIB TOSILATE MONOHYDRATE; OLAPARIB; PACLITAXEL; RUCAPARIB
    2024-516959-40-00 1 country 2021 n=136
    Ended
  • Bristol Myers Squibb International Corporation Commercial
    DOXORUBICIN HYDROCHLORIDE; FARLETUZUMAB ECTERIBULIN
    2023-504111-33-00 3 countries 2023 n=55
    Ended
  • Corcept Therapeutics Inc. Commercial
    RELACORILANT
    2024-517432-21-00 6 countries 2025 n=177 Orphan
    Recruiting
  • Merck Sharp & Dohme LLC Commercial
    MK-4830; PEMBROLIZUMAB
    2023-505005-16-00 4 countries 2022 n=32
    Ended
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS Academic
    RUCAPARIB
    2024-516632-99-00 1 country 2021 n=300 Orphan
    Ended
  • Nord Ostdeutsche Gesellschaft Fuer Gynaekologische Onkologie e.V. Academic
    NIRAPARIB TOSILATE MONOHYDRATE
    2022-502559-69-01 6 countries 2024 n=640 Orphan
    Recruiting
  • Nord Ostdeutsche Gesellschaft Fuer Gynaekologische Onkologie e.V. Academic
    PEMBROLIZUMAB
    2023-508155-40-00 1 country 2022 n=33
    Ended
  • Vall D Hebron Institute Of Oncology Academic
    IMP not specified
    2024-517363-24-00 1 country 2024 n=100
    Recruiting

Phase III/IV

1 trial
  • AbbVie Deutschland GmbH & Co. KG Commercial
    BEVACIZUMAB; CARBOPLATIN; DOXORUBICIN HYDROCHLORIDE; GEMCITABINE; MIRVETUXIMAB SORAVTANSINE; PACLITAXEL; PREDNISOLONE ACETATE
    2022-501606-35-01 11 countries 2024 n=110 Orphan
    Recruiting

Phase IV

1 trial
  • Uniwersytet Medyczny W Lublinie Academic
    IMP not specified
    2023-509659-15-00 1 country n=332
    Pending

Phase I

1 trial
  • Seagen Inc. Commercial
    IMP not specified
    2023-503389-22-00 4 countries 2022 n=147
    Ended

Phase I (Other)

2 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    IMP not specified
    2023-506227-29-00 2 countries 2024 n=60
    Recruiting
  • AstraZeneca AB Commercial
    IMP not specified
    2025-522731-34-00 3 countries 2026 n=34
    Recruiting

Phase I (First in Human)

3 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    BRIMONIDINE TARTRATE; IMGN151; PREDNISOLONE ACETATE
    2023-506842-22-00 7 countries 2025 n=176
    Ended
  • Regeneron Pharmaceuticals Inc. Commercial
    CEMIPLIMAB, FIANLIMAB; REGN5668; SARILUMAB; UBAMATAMAB
    2022-501904-83-00 3 countries 2023 n=208
    Recruiting
  • Regeneron Pharmaceuticals Inc. Commercial
    CEMIPLIMAB; SARILUMAB; UBAMATAMAB
    2024-510783-23-00 5 countries 2020 n=237
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
AbbVie Deutschland GmbH & Co. KG Commercial 5 Phase III/IV, Phase I (Other), Phase II, Phase I (First in Human) 4
AstraZeneca AB Commercial 2 Phase I (Other), Phase III 2
AGO Research GmbH Commercial 2 Phase II, Phase III 1
Corcept Therapeutics Inc. Commercial 2 Phase II, Phase III 1
Regeneron Pharmaceuticals Inc. Commercial 2 Phase I (First in Human) 2
Nord Ostdeutsche Gesellschaft Fuer Gynaekologische Onkologie e.V. Academic 2 Phase II 1
Seagen Inc. Commercial 1 Phase I 0
Daiichi Sankyo Inc. Commercial 1 Phase II/III 1
Bristol Myers Squibb International Corporation Commercial 1 Phase II 0
Merck Sharp & Dohme LLC Commercial 1 Phase II 0
Canariabio Inc. Commercial 1 Phase III 0
Immunogen Inc. Commercial 1 Phase III 0
Mural Oncology Inc. Commercial 1 Phase III 0
pharmaand GmbH Commercial 1 Phase III 0
Fondazione Policlinico Universitario Agostino Gemelli IRCCS Academic 1 Phase II 0
Vall D Hebron Institute Of Oncology Academic 1 Phase II 1
Centre Oscar Lambret Academic 1 Phase III 0
Uniwersytet Medyczny W Lublinie Academic 1 Phase IV 0
New trials by year
2019
1
2020
2
2021
4
2022
5
2023
4
2024
5
2025
3
2026
1
← All indication landscapes